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Abstract
Previously, replicating adenovirus type 5 host range (Ad5hr)-HIV/SIV recombinant priming in combination with SIV envelope boosting,
resulted in significant, durable protection in 39% of rhesus macaques after SIVmac251 challenge. Both Env-specific antibody mediating ADCC, and
cellular immunity correlated with protection. Here we evaluate the relative immunogenicities of novel HIV proteins and their contribution to
protection in a SHIV89.6P model. All groups were primed with Ad-HIVenv89.6P, SIVgag239, and SIVnef239 recombinants. One group was not
boosted, one received HIV89.6Pgp140ΔCFI protein, and one a novel HIV-1 poly-peptide “peptomer”. The HIV89.6Pgp140ΔCFI protein in adjuvant
strongly boosted Env-specific antibody and memory T cell responses in blood and tissue, resulting in significant reductions in acute and set point
viremia. Macaques not boosted, showed a significant reduction in set point viremia, a full 32 weeks after the last Ad priming immunization. The
HIV peptomer-boosted group showed a trend toward chronic viremia reduction, but was not protected.
© 2008 Elsevier Inc. All rights reserved.Keywords: Replicating adenovirus vectors; prime/boost; HIV/SIV vaccines; SHIV89.6P challenge; Rhesus macaquesIntroduction
Despite decades of research aimed at developing an effective
HIV vaccine, the AIDS epidemic continues unabated. Among
the current candidates that are being evaluated, ones utilizing
viral vectors to deliver HIV genes to the immune system are of
most interest. Both replication-competent and incompetent
adenovirus (Ad) recombinant vaccine strategies are currently
being pursued. They are already known to exhibit protective⁎ Corresponding author. NIH, NCI, 41 Medlars Drive, Building 41, Room
D804, Bethesda, MD 20892-5065, USA. Fax: +1 301 402 0055.
E-mail address: guroffm@mail.nih.gov (M. Robert-Guroff).
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doi:10.1016/j.virol.2007.12.037efficacy in preclinical animal trials (Buge et al., 1997; Demberg
et al., 2007; Letvin et al., 2004; Liang et al., 2005; Malkevitch
et al., 2006; Patterson et al., 2004; Zhao et al., 2003a), as well as
proving to be safe and immunogenic in people (Catanzaro et al.,
2006). Recent trials involving the use of Merck's Ad5 trivalent
vaccine however, failed to show protective efficacy in two
separate cohorts of volunteers and were halted. Nevertheless,
additional Ad-based vaccines are in development and improve-
ments to these vectors should increase chances of future success.
An attractive feature of Ad vectors is that, depending on the
strain, they preferentially infect epithelial cells which line the
upper respiratory, gastrointestinal, and reproductive tracts.
Ninety percent of all HIV infections are acquired at mucosal
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targets CD4+ memory T cells which reside at these same sites
(Li et al., 2005b; Mattapallil et al., 2005; Veazey et al., 1998,
2000). Therefore, priming and expanding immune cells
responsible for blocking initial infection at the mucosa are vital.
Our lab has been developing and characterizing replicating
Ad-HIV/SIV recombinant vectors expressing multiple inserted
genes as immunogens in chimpanzees and rhesus macaques.
Historically, we have shown that our vectors can prime potent
cellular, humoral and mucosal immunity and in combination
with a protein boost, can further expand the breadth of the
immune response to protect from homologous and heterologous
HIV challenges of chimpanzees (Lubeck et al., 1997; Robert-
Guroff et al., 1998; Zolla-Pazner et al., 1998) and from virulent
SIVmac251 and SHIV89.6P challenges in rhesus macaques
(Demberg et al., 2007; Malkevitch et al., 2006; Patterson
et al., 2004; Zhao et al., 2003a). Immune correlates of protection
included Env-specific cellular immunity, and Env-specific
binding antibody which mediated antibody-dependent cellular
cytotoxicity (ADCC) (Gomez-Roman et al., 2005) but not
conventional in vitro neutralization of the challenge virus.
Importantly, it was additionally shown in chimpanzees by Peng,
et al. that Ad-HIVenv recombinant priming followed by an
HIVSF162 gp140ΔV2 protein boost effectively elicited neutra-
lizing antibodies to primary HIV isolates (Peng et al., 2005) and
broadly reactive antibodies capable of mediating ADCC across
clades (Gomez-Roman et al., 2006a,b).
The objective of the current study was to dissect the
contribution of a protein boost to protection as well as assess the
relative immunogenicities of novel HIV proteins. To accom-
plish this, we shifted to a SHIV89.6P challenge model in Mamu-
A⁎01-negative rhesus macaques and further evaluated immune
responses in multiple tissue compartments in order to identify
correlates of protection.
Previously, we were able to achieve dramatic protection in a
subset of rhesus macaques that cleared viremia or remained
aviremic following Ad type 5 host-range mutant (Ad5hr)-
SIVenv/rev priming coupled with an SIV “peptomer” boost
(Malkevitch et al., 2006; Patterson et al., 2004). The peptomer,
initially formulated based on the HIVMN sequence (Robey et al.,
1995, 1996), represents 18 amino acids located within part of
the CD4 binding site on gp120. When this linear peptide is
linked end to end, it acquires a secondary structure containing
α-helical and β-sheet conformation, proposed to be structurally
similar to the envelope on the surface of the virion. The
peptomer is capable of binding CD4. The site targeted by the
peptomer is composed of the β20–β21 component of the
bridging sheet that connects the inner with the outer domains of
gp120. This component is highly conserved across HIVand SIV
strains, and contains both B and T cell epitopes. Here we used a
HIV89.6P peptomer as boosting immunogen, not only because
HIV is more relevant than SIV to people, but to determine if the
potent protection observed in macaques boosted with SIV
peptomer would translate to the SHIV system.
Second, we used a homologous prime-boost approach con-
sisting of Ad5hr-HIV89.6Pgp140ΔCFI priming and boosting
with HIV89.6Pgp140ΔCFI expressed protein. Letvin and col-leagues previously showed that the genetically modified
HIV89.6Penv gene containing deletions of the cleavage site,
fusion peptide and interhelical domains was able to broaden
antibody responses to Env (Mascola et al., 2005), and when
incorporated into both DNA and a replication defective Ad5
vector, resulted in protection from a SHIV89.6P challenge in
rhesus macaques (Letvin et al., 2004). We hypothesized that
when expressed as a protein, this immunogen, following
homologous priming with replicating Ad5hr-HIV89.6P-
p140ΔCFI, would elicit protective antibody responses.
Finally, we also included a vaccine arm which was not
boosted, only primed with Ad recombinants, in order to clearly
evaluate the relative contribution of the Ad priming immuniza-
tions and protein boosts to immunogenicity and protective
efficacy. Prior to this study we had not tested the protective role
of recombinant priming alone in either SIV or SHIV rhesus
macaque models.
Lastly in retrospect, groundbreaking vaccine studies pub-
lished a few years ago which made use of the SHIV89.6P virus
challenge (Amara et al., 2001; Rose et al., 2001; Shiver et al.,
2002) included macaques that were positive for a MHC class I
allele, Mamu-A⁎01, known now to mediate natural control of
viral infection in part due to a dominant CD8+ T cell response
(Mothe et al., 2003; Zhang et al., 2002). Since then, only a
handful of studies have controlled for this variable in
subsequent vaccine studies by excluding them from immuniza-
tion groups (Demberg et al., 2007; Letvin et al., 2004; Liang
et al., 2005). While useful for in vivo monitoring of immunity
against dominant epitopes such as Gag p11c, Mamu-A⁎01-
restricted responses represent only a fraction of the complex
immunological response to the myriad of epitopes included in a
vaccine. Consequently, with regard to both immunogenicity and
protective efficacy, accurate comparison of vaccine modalities
can only be accomplished with exclusive use of Mamu-A⁎01
negative macaques.
Therefore, our goal here was to test the ability of novel
boosting immunogens to elicit humoral and cellular immunity
in Mamu-A⁎01 negative rhesus macaques and to compare
protective efficacy of these vaccine regimens, including Ad-
recombinant priming alone, among the immunization groups.
Results
Adenovirus recombinant priming elicits both HIV-Env and
SIV-Gag specific ELISpot responses which are boosted and
maintained following HIV89.6P gp140 protein immunization
As summarized in Materials and methods, three groups of six
monkeys each were mucosally primed with replicating Ad5hr-
HIV/SIV recombinants containing HIVenv89.6Pgp140ΔCFI,
SIVgag239, or SIVnef239. One group received no boost, the
other two were boosted at weeks 24 and 36 with either HIV89.6P
gp140ΔCFI envelope protein or HIV89.6P peptomer. Six control
monkeys received empty replicating Ad5hr vector, and half
were boosted with adjuvant alone or PBS.
Virus-specific IFN-γ+ ELISpot responses using freshly iso-
lated lymphocytes from PBMC were measured throughout the
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animals received identical Ad recombinant immunogens and
responses were averaged for ease in presentation. After one
immunization with replicating Ad recombinants, only low level
HIV Env- (Fig. 1A) and SIV Gag- (Fig. 1B) specific responses
were detectable 2 and 10 weeks later. A second priming immu-
nization, however, boosted both Env- and Gag-specific re-
sponses. Env-specific responses were significantly higher
compared to the control group both at week 14 (pb0.0001)
and week 22 (pb0.0001).
After the first immunization with gp140, Env responses were
significantly boosted (pb0.0001), peaking to an average of 332
spots and were maintained at a similar level up to the time of
challenge at week 44 (Fig. 1A). Moreover, throughout the entire
boosting period (weeks 26 – 44), the gp140 group exhibited
significantly higher Env ELISpots compared to non-boosted
(p=0.0026) and peptomer boosted (p=0.012) groups. In fact,
at all time points measured, the Env-specific responses in the
gp140 boosted group were significantly different from controlsFig. 1. ELISpot values in response to stimulation with HIV Env89.6P (A) or SIV Gag
week 26, groups I, II and III were identical and responses therefore were averaged
shown separately and designated as no boost, gp140, peptomer, or control. Group mea
with standard error of the mean (sem) bars given. Data from the week 34 time point r
difficulties. An asterisk denotes a significant difference in comparison to the controwith p values of 0.0022, 0.0087, 0.0044, and 0.0022 at weeks
26, 34, 38 and 44 respectively. Env-specific ELISpot responses
for the non-boosted and peptomer boosted macaques were
significantly elevated above control values at week 26, possibly
due to continued presentation following the replicating vector
prime, however, these differences were not manifested at later
times during the immunization course.
Two priming immunizations with Ad recombinants were also
required to elicit a significant response to SIV Gag for the im-
munized macaques compared to controls at week 14 (p=0.0003)
and week 22 (p=0.0013), as seen in Fig. 1B. Interestingly, each
subsequent boost with gp140 was associated with elevated SIV
Gag-specific ELISpot responses that were significant versus
controls at the level of p=0.0022 and p=0.017 at weeks 26 and
38, and over the entire boosting interval in comparison to both the
control (p=0.0072) and peptomer boosted macaques (p=0.014).
We have previously observed this phenomenon (Zhao et al.,
2003a; Patterson et al., 2003) and attribute it to either an adjuvant
effect, since here only the gp140 group received MPL-SE, or to239 (B) overlapping peptide pools over the entire immunization course. Prior to
to represent the entire immunized group. After boosting, individual groups are
ns showing the number of spots per million PBMCs for each macaque are shown
eflecting SIV Gag responses for all macaques were unavailable due to technical
l response for that time point. Associated p values are provided in the text.
Table 1
Peak virus-specific T cell proliferative responses
Group Env 89.6P AT-2 89.6P SIV Gag SIV Nef Peptomer
Post priming
Immunized 8.1±1.7 7.6±1.4 4.3±0.5 2.3±0.5 1.9±0.2
Control 0.9±0.1 2.0±0.5 1.5±0.4 3.0±1.1 2.1±0.5
Post boosting
No boost 5.9±2.3 6.8±1.8 2.7±0.6 6.9±2.1 3.0±0.9
Gp140 7.1±1.6 8.8±2.3 1.8±0.4 4.6±2.6 3.2±0.7
Peptomer 6.4±1.8 10.4±1.4 5.5±1.6 4.8±2.3 6.3±1.2
Control 0.7±0.2 1.7±0.5 1.6±0.3 1.7±0.6 2.6±0.6
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providing a general CD4+ T helper response. Elevated Gag
responses in comparison to control levels were not detectable,
however, for any immunization group at challenge (week 44) at
which time intra-group values were highly variable. As with the
Env-specific responses, Gag-specific responses were signifi-
cantly different from controls for both the non-boosted (p=0.026)
and peptomer boosted (p=0.015) groups only at week 26.
Potent HIV Env-specific T cell proliferative responses are
induced after Ad priming, and sustained over the boosting
period for all macaques
Peak proliferative responses over the priming and boosting
phases of immunization for all antigens evaluated are shown in
Table 1. Additionally, Env-specific responses tested at each time
point following stimulation with gp140 protein, are shown in
Fig. 2. Similar to the ELISpot profile, a second Ad immuniza-
tion was required to induce significant proliferative responses
for the immunized macaques versus controls at a level of
pb0.0001 for both weeks 14 and 22 (Fig. 2). At week 26, two
weeks after the first protein boost, groups boosted with HIV
peptomer or gp140 exhibited significantly greater Env-specific
responses compared to controls (p=0.0087 and p=0.0065,
respectively), with the gp140 boosted group additionally
exhibiting significantly greater responses than the non-boosted
group (p=0.0065). At all subsequent time points, however, the
non-boosted group showed increasingly higher Env-specificFig. 2. T cell proliferative responses after stimulation with HIV89.6P Env protein. All
are averaged together until boosting. Group means are shown±sem. The double ast
significantly different from the controls, it is also different from the non-boosted groresponses, with differences in comparison to the controls
actually peaking at the time of challenge (p=0.0043 for weeks
34, 38 and 44). The slow, gradual acquisition of proliferative
responses to Env in this non-boosted group could be an as-yet-
unobserved feature of replicating Ad vectors, either due to the
continued presentation of antigen to the immune system or via a
unique mechanism of presentation. In addition, the gp140
boosted macaques continued to maintain responses over weeks
34 to 44 significantly greater than control levels (p=0.0043 for
each). The peptomer group also exhibited significant prolif-
erative responses in comparison to the control group (p=0.0043
at weeks 34 and 44).
Peak responses were similar across groups when aldrithiol-2
(AT-2) inactivated SHIV89.6P virions were used to stimulate
PBMC (Table 1). Moreover, during priming and boosting, all
groups continued to exhibit significantly higher responses at all
time points versus controls (pb0.026 for no boost group,
pb0.0087 for gp140 group, and pb0.0043 for peptomer
boosted group) except at the time of challenge, when only
peptomer boosted macaques were comparatively higher
(pb0.0043) (data not shown).
Proliferation in response to SIV Nef stimulation was more
variable within each immunization group and therefore while
peak values were elevated during the boosting phase (Table 1),
only the week 38 time point showed significant differences for
the non-boosted and gp140 boosted groups above control
(p=0.0022 for each).
Although less potent than Env, Gag-specific T cell prolif-
eration was also significantly higher in comparison to controls
following the second Ad priming (peak SI of 4.3, Table 1), with
p=0.0002 at week 14, and p=0.0004 at week 22. In contrast to
the ELISpot results, boosting with gp140 did not result in
detectable proliferative responses to Gag during this period.
However a single peptomer immunization did significantly
boost responses to Gag at week 26 (p=0.0022), that were sus-
tained until the time of challenge, but at lower levels (p=0.03).
In fact, the peptomer boost elicited the broadest virus-specific
proliferative responses, including responses to the SHIV89.6P
peptomer itself as well as to SIV Nef, SIV Gag, AT-2 inactivated
SHIV89.6P, and HIV89.6P gp140 (Table 1). The peptomerimmunized macaques received the same Ad recombinant priming vectors and so
erisk for the gp140 boosted group at week 26 denotes that in addition to being
up.
Fig. 3. Geometric mean binding antibody titers during immunization. Sera
collected at multiple time points during immunization were tested for reactivity
to HIV89.6P Env protein in an ELISA. Antibody titers were defined as the
reciprocal dilution at which the absorbance measured was two times above a
1:50 dilution of the control serum.
326 L.J. Patterson et al. / Virology 374 (2008) 322–337sequence is known to contain a potent T-helper epitope which
again, may stimulate responses to heterologous proteins such as
Gag and/or Nef via bystander activation.
Binding antibodies are induced after the second Ad
recombinant priming and boosted along with ADCC activity
after gp140 immunization
Using HIV89.6P gp140 recombinant protein to coat ELISA
plates, binding antibody levels were measured at numerous time
points after immunization. Geometric mean titers are shown in
Fig. 3. After the second Ad-recombinant immunization, anti-
Env binding titers rose to averages of 500–1290 for the three
immunized groups. The mean titer for the immunized macaques
was significantly higher than that of the controls (p=0.0004,
week 14; p=0.0063, week 22). Upon boosting with gp140,
mean titers dramatically increased two weeks following each
boost to 20,079 and 51,250 at weeks 26 and 38, respectively. At
all time points titers were significantly different from controls and
the non-boosted and peptomer boosted macaques (pb0.0002).
Anti-Env titers for the non-boosted and peptomer-boostedTable 2
Peak virus-specific immune responses
Pre-challenge
Group IFN-γ Elispot Proliferation Binding antibody ADC
Env Gag Env Env Env
No boost 50±24 126±39 5.9±2.3 173 10
Gp140 332±96 397±75 7.1±1.6 51,250 400
Peptomer 104±39 184±109 6.4±1.8 131 10
Control 11±21 118±65 .74±07 25 b10
Elispot reported as group mean SFC/106 PBMC. Proliferation reported as group mea
group means. % peak IFN-γ+ responses for either CD8+ or CD4+ CM or EM T cellmonkeys were not significantly different from controls at any
point after week 22.
ADCC activity was measured for all macaques at week 42,
two weeks prior to challenge. In accordance with the binding
antibody titers, only the gp140 boosted group mediated ADCC,
exhibiting a geometric mean titer of 400. All other groups had
titers of 10 or less (Table 2).
Neutralizing antibodies assessed by the luciferase assay on
TZM-bl cells were not detectable during the immunization course
against either SHIV89.6P pseudovirus or SHIV89.6P PBMC-grown
virus stocks at serum dilutions of 1:20 (data not shown).
Virus-specific, intracellular cytokine responses detectable in
both central and effector memory T cells in PBMC, lymph node
biopsies and BAL post Ad priming and gp140 protein boosting
Given that our vaccine was delivered mucosally and that
mucosal immunity is thought to be crucial to the efficacy of an
HIV vaccine, we prospectively collected and systematically
analyzed immune responses in multiple tissue compartments.
The lung is thought to be an effector site similar to the gut
(Picker et al., 2004), during SIV infection. However, few groups
have looked at immune cells elicited in the lung during
immunization. The lung is especially relevant here because our
immunization route is intranasal and intratracheal, with the
potential to elict a localized immune response in the upper
respiratory tract. We were able to repeatedly obtain fresh
lymphocytes from BAL, lymph nodes and blood for analysis of
T cell memory responses following stimulation with the same
Env, Gag and Nef peptide pools used for previous assays. Both
freshly isolated PBMC and inguinal lymph node biopsies
yielded sufficient numbers of lymphocytes which allowed
antigen stimulation and staining for both CD8+ and CD4+
T cells. Using a representative PBMC sample from week 14, we
show in Fig. 4 the gating strategy used for analyzing cytokine
specific central and effector memory T cell responses by
intracellular staining. Within the initial lymphocytic gate, the
total CD8+ or CD4+ lymphocytes were identified. Further
gating divided these into central (CD28+CD95+) or effector
(CD28−CD95+) memory populations (CM or EM) (Pitcher
et al., 2002). The IFN-γ-secreting central and effector memory
cells within each memory gate were enumerated and are
presented here as a percentage (Fig. 5). Although both CD4+Post-challenge
C % Env-specific memory
T cells
IFN-γ Elispot Env binding Antibody
PBMC LN BAL Env-Wk 1 Week 1 Week 2
0.09 0.27 0.15 130±104 101 44,863
1.09 1.7 2.21 414±143 6306 66,752
0.58 0.47 0.49 53±18 76 237,879
0.27 0.07 0.16 14±10 25 25
n SI±sem. Env-specific binding antibody and ADCC titers shown are geometric
s (see Fig. 5).
Fig. 4. Representative flow cytometric analysis of PBMC showing gating strategy used to enumerate cytokine secreting memory subsets. Shown are results after Env peptide stimulation for macaque CK6C at week 14,
two weeks post second Ad recombinant priming. After gating on lymphocytes, subgating was performed first on CD8β+ Tcells (or alternatively CD4+ Tcells), then on central (CD28+CD95+) and effector (CD28−CD95+)
memory cells. Finally, percent IFN-γ+ cells among both the central and effector populations were determined.
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328 L.J. Patterson et al. / Virology 374 (2008) 322–337and CD8+ IFN-γ+ cells were evident in blood and lymph nodes,
only CD8 responses are shown. Mean CD4+ responses were
overall lower and none was significantly different from the
mean of the control macaques. Only CD8+ memory T cells were
evaluated in BAL, as the number of cells obtained precluded
measurement of both CD4+ and CD8+ responses.
At week 14, two weeks after the second Ad priming
immunization, IFN-γ+ CD8+ CM and EM cells were expanded
in all tissues (Fig. 5A). Central memory IFN-γ+ cells were
detected in peripheral blood, after stimulation with Env
peptides, and to a lesser degree with Nef peptides. Although
low, significant levels averaging 0.22% for Env (p=0.0029)
and 0.13% for Nef (p=0.045) in blood were reached compared
to the control group. Both CM and EM IFN-γ+ secreting cellsFig. 5. IFN-γ+-specific CD8+ CM and EM responses in PBMC, LN and BAL after s
were processed and assayed immediately. After identifying the lymphocytic gate usi
populations were further identified as a subgate of the CD8+ lymphocytes. The per
average for each group±sem. As asterisk denotes that the group means are significawere observed in lymph node biopsies, however, unlike in the
blood, none were significantly different from the controls.
As predicted, the number of cytokine secreting cells in
response to antigenic stimulation was markedly higher in the
lung. The majority of cells were EM, but CM cells were also
evident, and in concert, both cell types responded to stimulation
with all three antigens. Nef-specific EM responses were highest,
averaging 1.63%, with 1.08% of CM responding as well. Gag
CM and EM levels reached 1.3% and 0.63% respectively, while
Env values were not much higher than control background
levels. Even though responses were quantitatively higher than
in blood, statistically they were not different from controls, due
in part to the high variability among animals in these groups as
evidenced by the error bars. Nevertheless, the overall trend for atimulation with HIV89.6P Env, SIV Gag, or SIV Nef peptide pools. All samples
ng FSC/SSC, central (CD28+CD95+) and effector (CD28−CD95+) memory cell
centage of each memory population secreting IFN-γ or TNF-α is shown as an
ntly different from the control group.
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readily apparent in a typical effector site such as the lung which
has also been reported elsewhere (Gauduin et al., 2006).
Finally, in addition to IFN-γ, a subset of macaques within
each group was also evaluated for TNF-α-secreting memory T
cells post-Ad priming at week 14 (Fig. 5A). While we did not
determine whether the same cell was secreting multiple cyto-Fig. 6. Viral loads following SHIV89.6P challenge. Viremia levels of individual cont
peptomer boosted macaques in panel D. Geometric means for each group are shown i
acute phase (day 8–week 3) and set point viremia (week 8–24) for groups listed.kines, it was clear that IFN-γ was not the sole cytokine secreted
in response to antigenic stimulation, as has been shown by other
groups (Wille-Reece et al., 2006).
A completely different profile was reflected in responses
measured two weeks after the last protein boost, at week 38
(Fig. 5B). In peripheral blood and lymph nodes, very few if any
IFN-γ+ secreting cells were detectable, be it CM or EM.rol macaques are shown in panel A, non-boosted in B, Gp140 in panel C, and
n panel E for comparison. Statistically significant differences were found during
Fig. 7. %CD3+CD4+ T cells in PBMC post challenge. Geometric means for each
group are shown.
Fig. 8. Neutralizing antibody titers post challenge. Geometric mean ID50
neutralization titers against a SHIV89.6P pseudovirus using the TZM-bl Luc cell
line are shown for all immunization groups post challenge.
330 L.J. Patterson et al. / Virology 374 (2008) 322–337However, the importance of analyzing multiple cytokines was
highlighted by the observation that more than 1% of all Env-
specific CM cells were TNF-α+ in PBMC of the gp140 boosted
macaques (Fig. 5B, bottom panel). In macaques boosted with
gp140, proliferation of Env-specific CD8+ IFN-γ+ cells were
identified in BAL, averaging 1.60% of all CM cells. This
observation again points to the value of measuring immune
responses at this and other effector sites when possible in order
to assess the impact of vaccination and potential correlates of
protection. Gag-specific responses for CM and EM were readily
measured in the gp140- and peptomer-boosted monkeys as well,
but were not statistically significant compared to controls.
Rectal pinch biopsies were also collected prior to immuniza-
tion and following the Ad priming and protein boosting phases
of the vaccine regimen in order to evaluate memory T cell
responses. However, meaningful interpretation of the data was
not possible since cells recovered were too few in number.
Therefore, results are not reported here.
Gp140 boosting resulted in significant reduction in acute phase
and set point viremia, while the non-boosted group exhibited
reduced set point viremia
Results of the intravenous challenge with 90 MID50 of
SHIV89.6P are shown for individual macaques (Figs. 6A–D)
along with the geometric mean of each group (Fig. 6E). Sig-
nificant reduction of acute phase viremia (days 8 to 21) by
1.5 logs was evident for the gp140 boosted macaques in com-
parison to controls (p=0.028 by the Wei–Johnson test), but not
to the other immunized groups. Although a slight reduction in
acute viremia (0.5 logs) was measured, no significant differ-
ences were observed for either the non-boosted or peptomer
boosted groups versus controls. The set point was defined here
as the median of the log viral loads over weeks 8–24 (days 56–
168). The non-boosted and gp140 boosted macaques exhibited
a significant reduction in set point viremia (roughly 3 logs) in
comparison to control macaques (p=0.0022 for both). For the
peptomer boosted group there was a reduction in viral load
compared to controls over the set point phase except at week 12(day 84), where a transient rise in viral loads was observed. This
increase contributed to the lack of a significant difference
between the peptomer group and the controls (p=0.093).
Preservation of CD4+ T cells is known to be a distinct
correlate of protection in the SHIV challenge model (Igarashi
et al., 2002; Reimann et al., 1996); therefore the cells were
monitored here following SHIV89.6P challenge. The reduction
in percent CD3+ CD4+ cells post-challenge for all groups is
shown in Fig. 7. There was a significant preservation of CD3+
CD4+ Tcells for all the immunized groups compared to controls
with pb0.01 for day 28 and thereafter. The CD4 counts were
highly correlated with viral loads during both the acute and
chronic phases of infection (p=0.0077 for days 14–56 and
p=0.0014 for days 112–196). Due to variability within each
immunization group, there were no significant differences ob-
served between them.
Furthermore, to elucidate the basis for the significantly
reduced acute viremia in the gp140-boosted group of macaques,
and the overall lower viral load seen in this group during the
chronic phase of infection, we investigated whether any immune
responses were correlated with viremia outcomes. Although no
single pre-challenge immune response in the gp140-boosted
macaques was significantly correlated with either acute or
chronic reductions in viral burdens, this group of animals
displayed the most potent vaccine-induced immunity over the
course of immunization as summarized in Table 2. The gp140-
boosted macaques exhibited strong Env and Gag specific
ELISpot responses, Env proliferation, and Env-specific binding
antibodies that mediated ADCC activity during the boosting
period and extending to the time of challenge. The greater level
of responses overall in this group suggests a basis for the better
challenge outcome. Responses measured in the non-boosted
group were not predictive of control of chronic phase viremia. In
the absence of a protein boost however, this group displayed a
strong Env and Nef-specific proliferative response at the time of
challenge which we speculate may have contributed to control.
With regard to post-challenge immune responses, an
anamnestic IFN-γ+ ELISpot response was seen 1 week after
challenge for the gp140-boosted group (Table 2) which was
significantly different from all other groups (p=0.0022 vs
control or peptomer groups, p=0.041 vs no boost group).
However, it was not significantly correlated with reduced peak
331L.J. Patterson et al. / Virology 374 (2008) 322–337or set point viremia. Binding antibody titers at week 1 post
challenge for all immunized macaques correlated significantly
with reduced viremia at week 16 post challenge (p=0.017).
This was largely attributable to the persistent binding antibody
response induced by the pre-challenge vaccine regimen
exhibited by the gp140-boosted macaques (Table 2). By week
2 post-challenge, a strong anamnestic antibody response was
observed for all immunized groups, whereas titers in control
animals remained low (Table 2). By four weeks post-challenge,
geometric mean binding titers for all immunized groups ranged
from 210,000–521,000, while control titers exhibited a mean of
100 (data not shown). This outcome reflects not only the gp140
boosting, but also the priming with Ad5hr-recombinants ex-
pressing the env gene.
Neutralizing antibody was first observed in all the immunized
macaques four weeks post-challenge with geometric mean titers
ranging from 78–138 (Fig. 8). The titers gradually increased to
geometric means of 420–1100 by 20 weeks post-challenge.
During this same time period, control macaques exhibited a
comparatively delayed and low level peak neutralizing titer of
50. The neutralizing antibody response, clearly primed by the
immunization regimen, did not impact the acute phase of
infection, and like the induction 2 to 4 weeks post-challenge of
elevated binding antibody titers, did not necessarily predict the
observed differences in chronic viremia between groups.
Discussion
Here we report results of a comparative study of the con-
tribution of novel envelope protein boosts to immunogencity
and protective efficacy in a vaccine regimen using replicating
Ad5hr-HIV/SIV recombinant priming in rhesus macaques.
Significant reduction in acute viremia was seen in the gp140-
boosted group, signaling a clear benefit of the protein boost in
the vaccine regimen. Strong Env-specific antibody and T cell
responses were readily detected. Earlier results from our group
using an SIV macaque model showed that binding antibodies at
the time of challenge – later determined to mediate ADCC –
correlated with reduction in acute phase viremia following a
SIVmac251 challenge (Gomez-Roman et al., 2005). Here,
following evaluation of ADCC activity against target cells
coated with HIV89.6P gp140ΔCFI protein, such a correlation was
not observed. However, the ADCC mediating antibody titers of
1:400 were lower compared to those that correlated with acute
phase protection in the previously reported SIV challenge study
(titers of 1:100,000). More extensive analyses of ADCC activity
against SHIV89.6P-infected cells pre- and post-challenge, other
Fc receptor-mediated antibody activities, and mucosal anti-
bodies are on-going in order to assess the possible contribution
of envelope antibody to acute phase protection. The elevated
binding antibody in the gp140-boosted animals which persisted
post-challenge, together with an anamnestic SIV-specific IFN-γ
ELISpot response seen one week post challenge may have
contributed to the better protection observed, although taken
individually a correlation was not revealed. While binding
antibody responses are not generally associated with control of
chronic viremia, we recently showed a combination Ad-HIVtat/env prime, protein boost immunization regimen elicited
enhanced binding antibodies at the time of challenge that
provided an explanation for greater control of chronic viremia,
although a direct correlation was not observed (Demberg et al.,
2007). These antibodies were non-neutralizing, but their other
functional properties have yet to be examined.
Virus-specific immune responses associated with signifi-
cantly reduced chronic viremia in the gp140 macaques could
not be elucidated, save for the 1 week post-challenge antibody
response that was correlated with reduced viremia at week 16
during the chronic phase. We speculate that the sum total of
immune responses were associated with the overall better
challenge outcome in the gp140 boosted animals. Further, the
possible contribution of the adjuvant used in the gp140 boosting
regimen to the challenge results cannot be discounted, since the
other immunized macaques received only PBS or antigen
diluted in PBS. However, half of the control macaques received
adjuvant following priming with Ad empty-vector with no
corresponding increase in non-specific immune responses
detected in comparison to PBS controls. Appropriately designed
studies using the identical boosting protein with or without
adjuvant would address this.
The replicating Ad5hr recombinants primed for expansion of
virus-specificmemoryCD8+ Tcells, both in peripheral blood and
lymph nodes, although elevated numbers of cytokine producing
memory CD8+ Tcells were seen in the lung (Fig. 5A), consistent
with the intranasal/intratracheal immunization routes. These
virus-specific memory cells persisted through the boosting phase
at the local upper respiratory site and in peripheral blood, as
shown by the TNFα-secreting cells, particularly in the gp140 and
peptomer boosted groups (Fig. 5B). Memory T cells did not
appear to persist in the non-boosted group, however. This
response pattern does not correlate with the challenge outcome,
in which the non-boosted and gp140-boosted groups showed the
best protection during the chronic phase, whereas the peptomer
group was not statistically different from the control macaques.
This observation suggests that elements in addition to T-cell
immunity, perhaps antibody responses, were contributing to
protection in the gp140-boosted group. Further, the result
suggests vaccine-elicited memory T-cells that contributed to
protection in the non-boosted group were perhaps located in
tissues other than those reported here. Alternatively, populations
of vaccine-elicited memory T cells may have been present, but
secreting cytokines other than IFN-γ or TNFα. In support of this
notion, we observed a general two-fold expansion of total CD8+
memory cells at week 38 in PBMC of both the non-boosted and
gp140 boosted groups (data not shown). As both groups effec-
tively controlled set point viremia in comparison to the peptomer
and control groups, these cells may have possessed other func-
tions that contributed to viremia control.
The fact that Ad recombinant priming alone with no inter-
vening boost gave a significant three-log reduction of chronic
viremia following challenge 32 weeks after the last immuniza-
tion is remarkable and compares favorably with an earlier study
also conducted in Mamu-A⁎01 negative rhesus macaques
(Letvin et al., 2004). In that study, Letvin et al reported that a
vaccine regimen consisting of three primes with DNA vaccines
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challenge stock) and a single non-replicating Ad5 boost
containing identical immunogens also resulted in a three-log
reduction in chronic viremia following challenge with the same
SHIV89.6P stock. However, the challenge was administered only
12 weeks following the last immunization, and the challenge
dose was 50 MID50, rather than the 90 MID50 used here. As also
observed in the gp140 boosted group, no clear immune correlate
was associated with chronic control of viremia in the non-
boosted group. The observation that Env-specific proliferative
responses were detectable however, gradually peaking
32 weeks after priming with no intervening boost is new, and
could be an important hallmark of a replicating Ad vector.
Immunization resulting in a slow expansion of virus specific
memory T cells either due to a prolonged exposure to antigen or
a unique mechanism of antigen presentation would be optimal.
A novel SIV peptomer boost had previously afforded strong
protection from a pathogenic SIVmac251 challenge (Malkevitch
et al., 2006; Patterson et al., 2004), leading us to hypothesize
that a comparable HIV peptomer boost would protect from an
appropriately matched SHIV89.6P challenge. Although the HIV
peptomer contains both B and T cell epitopes, it was not as
immunogenic as the HIV89.6P gp140ΔCFI protein administered
in adjuvant, and subsequently failed to significantly protect
rhesus macaques from challenge.
It was unexpected that no enhancement in binding or
neutralizing antibody was elicited by peptomer boosting prior to
challenge. However post challenge, week 2 binding antibody
and week 8 neutralizing titers were 3–5-fold and 1 log higher,
respectively for the peptomer boosted group compared to the
gp140 and non-boosted groups. This suggests that potentially
unique binding and neutralizing antibody responses were
primed by peptomer immunization. Repeated immunization
and/or with higher doses of HIV peptomer could possibly have
achieved protective levels. The immune correlates of protection
after SIV peptomer boosting responsible for prior control of the
more virulent SIVmac251 challenge have yet to be determined.
Therefore we cannot attribute the lack of protection seen here in
the peptomer-boosted group to a specific immune mechanism.
The HIV peptomer elicited Env-specific ELISpot responses
comparable to those observed following immunization with the
SIV peptomer (Patterson et al., 2003, 2004). Greater prolif-
erative responses were induced, although the assays here were
conducted on fresh cells in contrast to the earlier study where
viably frozen cells were used. Neither the SIV nor HIV peptomer
boosts elicited comparatively high titered envelope antibody
responses. It is possible that the SIV peptomer presented a
conformational epitope, not reproduced by the HIV peptomer or
by test antigens in assays used to evaluate immune responses,
which was associated with protection. This speculation requires
further structural analysis of both the SIV and HIV peptomers.
While identical control of acute viremia was seen for both
non-boosted and peptomer-boosted groups, it was puzzling that
only the non-boosted group showed significant control of
chronic viremia while the peptomer-boosted group did not.
Given that peptomer elicited a potent T cell helper response it is
worth speculating that immunization resulted in expansion ofvirus-specific T cells that – in the absence of protective antibody
titers during acute phase to blunt viremia – could be det-
rimental, by giving the virus a greater number of targets, tipping
the balance in favor of infection, and resulting in lesser control
of long term chronic viremia.
Lastly, our mucosal vaccination route coupled with the
natural transmission and targeting of Ad to mucosal inductive
sites suggests that the intravenous challenge administered here
might not have demonstrated the greatest potential of the
vaccine regimen in terms of protective efficacy. Control of
viremia – especially during the acute phase – might have been
greater after a mucosally delivered challenge with a CCR5-
using SHIV. Such pathogenic SHIV challenge stocks have been
prepared and fully evaluated and will aid us tremendously in
evaluating the efficacy of our vaccines (reviewed in Vlasak and
Ruprecht, 2006).
Human clinical trials of Merck's non-replicating Ad5-HIV
gag-pol-nef vaccine were recently stopped due to lack of
efficacy. Although data are still coming to light, the suggestion
that people with high anti-Ad5 titers may have been more
susceptible to HIV infection is noteworthy for the entire vaccine
field and is clearly relevant to our replicating Ad-recombinant
approach. The trend for increased susceptibility to HIV infection
was most pronounced in a subset of vaccinees which received
three high dose Ad5-HIV recombinant immunizations. Detailed
information concerning the immune responses elicited in this
subset of people along with virological and sociological data will
be necessary to validate the possible enhancement and under-
stand the basis for the observed trial outcome. In the meantime,
one can speculate that pre-existing Ad5 memory cells may have
been activated following re-exposure to the Ad5-based vaccine,
thereby inducing CD4+ T cell activation, resulting in greater
numbers of target cells for HIV infection and replication. This is
a testable hypothesis, and studies to address this question are
already being planned by the vaccine community.
With regard to our replicating Ad vaccine approach, there are
important differences in comparison to the Merck non-replicating
Ad5-HIV vaccine. Our vaccine for humans will be based in Ad
type 4, which has low seroprevalance in the U.S. (Ludwig et al.,
1998). Worldwide seroprevalence will need to be ascertained,
however there is no reason to expect geographical differences.
Further, sequential boosting is planned, first with an Ad7-based
vaccine in order to circumvent any vaccine-elicited anti-Ad4
immunity, and subsequently with an envelope protein subunit in
order to generate potent antibody responses. We believe cellular
and humoral immune responses together will elicit greater pro-
tective efficacy. Finally, we have previously shown in non-human
primates that replicating Ad-recombinants elicit more potent anti-
HIV cellular immunity and better prime antibody responses
compared to non-replicating Ad recombinants (Peng et al., 2005),
suggesting that enhanced immunity will also be generated by the
replicating vaccine in people. While plans for a phase I trial of the
replication-competent Ad4 vaccine approach are underway, the
human studies will move forward cautiously until the vaccine
community learns whether the observed trends in the Merck trial
are statistically significant and gains a full understanding of the
mechanisms underlying the observed results.
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when administered alone – elicit long-lasting immunity, pro-
viding strong reduction in chronic viremia following challenge
up to 32 weeks after immunization. Further, the benefit of a
protein boost coupled with our Ad-recombinant priming
scheme is clearly shown in this study. Others have shown a
similar benefit following priming with DNA or other non-
replicating vectors (Cristillo et al., 2006; Shu et al., 2007). The
envelope boost contributed to reductions in both acute phase
and chronic viremia. It not only elicited humoral immunity, but
in combination with replicating Ad recombinant priming addi-
tionally boosted cellular immunity. The underlying mechanism
for this expansion has not been elucidated, however routine
exploitation of such a vaccine-induced response would be worth
incorporating into future strategies for HIV vaccine develop-
ment. Further improvement in the design of the envelope
protein used for boosting as well as characterization of immune
responses induced by priming alone should only increase the
potential of the Ad-recombinant prime/protein boost approach.
Materials and methods
Immunization and challenge schedule
Twenty-four juvenile male Indian rhesus macaques, negative
for SIV, simian retrovirus type D, and simian T-cell leukemia
virus, were housed according to NIH animal care guidelines at
Bioqual, Inc., Rockville, Maryland. All animals were Mamu-
A⁎01 negative. One macaque, CJ9T, tested positive for the
B⁎17 allele which is overrepresented in long-term non-
progressor macaques (Yant et al., 2006) but not sufficient to
predict SIV disease outcome (Wojcechowskyj et al., 2007).
The immunization scheme is shown in Fig. 9. The twenty-
four macaques were divided equally into four groups. Groups I,
II, and III received identical replication-competent Ad5hr-HIV/
SIV recombinant priming immunizations encoding HIV89.6P
gp140ΔCFI (T. Demberg et al., submitted), SIVgag239 (Zhao
et al., 2003b), and SIVnef239Δ1–14 (Patterson et al., 2003) at
weeks 0 (intranasal and oral routes) and 12 (intratracheally) at a
dose of 5×108 pfu/recombinant for a total of 1.5×109 pfu/Fig. 9. Immunization regimen and challenge schedule. As detailed in Materials and m
0 and 12 with three Ad recombinant vectors each encoding HIV89.6P gp140ΔCFI, SI
no boost, soluble HIV89.6Pgp140ΔCFI protein or an HIV89.6P peptomer. A control gr
match the boosting groups. Eight weeks after the last boost, all macaques were chalmacaque/route of immunization. Procedures for the intranasal
(0.25 ml per nostril), oral (0.5 ml via stomach tube), and
intratracheal (0.5 ml) administrations have been described
previously (Zhao et al., 2003a). A plasmid containing the
HIV89.6Pgp140ΔCFI gene has been described (Letvin et al.,
2004) and was generously provided by Dr. Gary Nabel, VRC,
NIH, for construction of the Ad5hr-recombinant and prepara-
tion of expressed protein as described elsewhere (T. Demberg
et al., submitted). Groups were distinguished by boosting
immunogens administered intramuscularly at weeks 24 and 36
at a dose of 100 μg/macaque. Group I received no boost, only
PBS, and Group II, HIV89.6P gp140ΔCFI protein in 50 μg
monophosphoryl lipid A-stable emulsion (MPL-SE) adjuvant
(Corixa) at a final 1:10 dilution. Group III received a HIV89.6P
peptomer composed of repeating 18-mers covalently linked
end-to-end, representing amino acids 419–436 of the envelope
and formulated in PBS (Robey et al., 1995). Group IV controls
received a comparable dose of empty replicating Ad5hrΔE3
vector (no insert) with 3 macaques getting MPL-SE and 3
receiving PBS during the boosting phase. All macaques were
challenged intravenously at week 44 with 90 MID50 of a
SHIV89.6P challenge stock obtained from Nancy Miller,
Division of AIDS, NIAID, NIH, and originally prepared and
titered by Keith Reimann and Norman Letvin, Beth Israel
Deaconess Medical Center, Harvard Medical School.
Tissue collection and processing
Peripheral blood samples were collected at serial time points
throughout the study. Lymphocytes were isolated by density
gradient centrifugation over Ficoll-Paque Plus (GE Healthcare,
USA), and used either fresh or were frozen in fetal bovine serum
(FBS, Invitrogen) containing 7% DMSO, and stored in liquid
nitrogen until use. In addition, at weeks 0, 14 and 38 post
immunization and weeks 2 and 12 post challenge, inguinal
lymph node biopsies and bronchio-alveolar lavage (BAL)
samples were processed and directly used in assays. Lymph
nodes biopsies were sliced finely with a scalpel, and pressed
through a 70 μm filter in order to isolate lymphocytes. For BAL,
30–50 ml of fluid was collected after deep flushing of oneethods, four groups of sixMamu-A⁎01 negative macaques were primed at weeks
Vgag239 or SIVnef239Δ1–14. Groups differed by boosting immunogen, receiving
oup received empty Ad vector followed with MPL-SE adjuvant or PBS only to
lenged intravenously with 90 MID50 of a SHIV89.6P stock.
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of supernatant frozen. The cell pellet was resuspended in 10 ml
of PBS, then layered onto a Percoll (Sigma, St. Louis, Missouri)
gradient consisting of 2 ml of 65% Percoll diluted in RPMI-
1640, followed by 2 ml of 35%. After centrifugation for 30 min
at 400 ×g, the whitish live cell layer was collected at the
interface, the lymphocytes counted and resuspended in 3 ml of
R10 (RPMI-1640 plus 10% heat inactivated fetal bovine serum,
1 mM L-glutamine and 100 U/ml Pen-Strep; Invitrogen). After
overnight incubation, the cells were used immediately in
immune assays. In addition to the above tissues, rectal pinch
biopsies were also collected during this study. Unfortunately
low cell numbers after processing precluded their inclusion in
further data analyses.
Measurement of cellular immunity
IFN-γ ELISpot
Fresh PBMC were counted and plated in triplicate into a 96-
well plate at a density of 105 and 5×104 cells/well in 100 μl R10
media. Overlapping peptides representing HIV and SIV genes
were added at a concentration of 1 μg/ml of each peptide and the
plate incubated overnight at 37 °C. Peptide pools consisting of
15-mers overlapping by 11 amino acids for SIV239 Gag and
SIV251 Nef, and 20-mers overlapping by 10 for HIV89.6P Env
were obtained from the AIDS Research and Reference Reagent
Program, NIAID, NIH. Control wells containing media alone or
media alone plus the appropriate DMSO concentration were
included, as well as a positive ConA (Sigma) control at 5 μg/ml.
The next day, the plates were transferred to a 96-well plate that
had been previously coated with anti-IFN-γ monoclonal anti-
body MD-1, and blocked with 2% BSA (200 μl/well) for 1 h at
37 °C. After a 5 h incubation at 37 °C, the plates were developed
according to kit instructions (U-Cytech, Utrecht, The Nether-
lands). Spots were averaged, and the average of background
spots was subtracted to obtain the net number of spots reported.
Total spot forming cells (SFC) are shown/106 PBMC. On rare
occasions, data were eliminated from analysis when the negative
control background wells exceeded 125 SFC/106 PBMC.
Proliferation
Fresh PBMC were used to measure SIV251 Gag-, SIV251
Nef-, and SHIV89.6P gp140 Env-specific lymphoproliferative
responses at each time point tested. Purified proteins which
matched HIV/SIV inserts were used for stimulation. Addition-
ally, AT-2 inactivated SHIV89.6P supplied by Dr. Jeff Lifson and
Julian Bess (NCI-Frederick, Frederick, MD) was used along
with an equal amount of empty SUPT1 microvesicles, which
served as a negative control. A total of 3×105 cells/well plus
4 μg protein/well were plated in triplicate in a 96-well plate. On
the fourth day of incubation, 1 μCi of 3H-thymidine was added
to each well and the plate harvested onto a Perkin Elmer filter
mat the next day for determination of thymidine incorporation
using a Perkin Elmer Microbeta Trilux beta counter. The
stimulation index (SI) was calculated as the mean counts per
minute for the stimulated well divided by the mean counts for
the media only wells.Intracellular cytokine staining
At weeks 0, 14 and 38 pre-challenge and weeks 2 and 12 post-
challenge freshly isolated PBMC, lymph node and BAL samples
were analyzed by intracellular cytokine staining for IFN-γ
secreting CD8+ and CD4+ memory T cells in response to
stimulation with the same SHIV89.6P Env, SIV239 Gag and SIV251
Nef peptides used for the ELISpot assay (see above). Fresh
lymphocytes were counted and adjusted with R10 to 1–2×106
cells/ml for each stimulation condition, including a no-peptide
control and a staphyloccal entertoxin B (SEB) positive control
(0.2 μg/ml). After a 1 h incubation at 37 °C, 2 μl/ml of GolgiStop
(BD Biosciences) was added and the tubes incubated an
additional 5 h after which they were washed and stained
according to previously published protocols (Demberg et al.,
2007) using permeabilization/fixation solutions A and B from
Invitrogen and antibodies from BD Pharmingen unless specified
otherwise. Briefly, after washing twice with PBS, cells were
surface-stained for 20 min using three separate antibodies
including CD28-FITC (Clone 28.2), CD95-PE (Clone DX2),
CD8β-ECD (Clone 2ST8.5H7, BeckmanCoulter) or CD4-PerCP
(Clone L200). After incubating with solution A for 15 min with
washing before and after, the cells were incubated with solution B
containing anti-IFNγ-APC (Clone B27) for 20 min, washed,
pelleted and fixed with 3.7% formaldehyde diluted in PBS. At
least 100,000 events were collected within the lymphocytic gate
using a FACScalibur and Cellquest software. A positive response
was defined as one significant over unstimulated cells at the two-
tailed α=0.05 level by the continuity adjusted chi-squared test.
Due to the loss of power for detection, a response comparisonwas
excluded if the harmonic mean of the gated central or effector
memory event numbers was less than 300.
Measurement of humoral immunity
Serum binding antibodies reactive with SHIV89.6P gp140
Env protein were measured in an ELISA assay as previously
described (Buge et al., 1997). The reciprocal of the dilution at
which the absorbance was two times greater than a 1:50 dilution
of the control serum was defined as the antibody titer.
ADCC activity of macaque serum antibodies was assessed
using the rapid fluorometric ADCC assay (RFADCC) described
elsewhere (Gomez-Roman et al., 2006a,b). Briefly, CEM-NKr
target cells (AIDS Research and Reference Reagent Program,
National Institutes of Allergy and Infectious Diseases) were
coated with HIV89.6P gp140 and double stained with the mem-
brane dye, PKH-26 (Sigma Aldrich) and the vital dye, CFSE
(Molecular Probes). Labeled target cells were resuspended in
RPMI 1640 medium containing 10% FCS (R10) and allowed to
react with heat inactivated (56 °C, 30 min), serially diluted
macaque sera in a 96-well microtiter plate for 15 min at room
temperature. Human effector cells were added at a E:T ratio of
50:1. The reaction mixture was incubated at 37 °C in 5% CO2
for 4 h and fixed with 3.7% paraformaldehyde for flow
cytometry acquisition (FACSCalibur instrument, Becton Dick-
inson, San Jose, CA, USA). Fifty thousand non-gated events
from duplicate wells were acquired within 18 h using CellQuest
software and data analysis was performed using WinMDI 2.9.
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membrane-labeled target cells that lost the viability dye, i.e.:
percentage of CFSE negative within the PKH-26 high gate. ADCC
titer is defined as the reciprocal serum dilution at which the
percent ADCC killing was greater than the mean percent killing
of negative control sera plus 3 SDs.
ID50 neutralizing antibody titers were determined using the
TZM-bl Luc cell line and either a SHIV89.6P pseudovirus or
SHIV89.6 PBMC-grown stock as already described (Demberg
et al., 2007; Li et al., 2005a). Titers are defined as the reciprocal
plasma dilution at which there was a 50% reduction in relative
luminescence units (RLUs) compared to virus control wells
which contained no test sample.
Measurement of viral RNA
A description of the nucleic acid sequence-based amplifica-
tion technique (NASBA) used in this study was detailed in
previous publications (Malkevitch et al., 2006; Romano et al.,
2000). All samples were initially screened using this ECL-based
assay which has a sensitivity of b2000 viral RNA copies per
input plasma volume (generally 100 μl). When lower sensitivity
was required, a real-time NASBA assay with a sensitivity of
b50 copies/ml was utilized, thereby defining the sensitivity of
detection as 50 copies.
Statistical analyses
Comparisons between groups at individual times were
assessed using the exact Wilcoxon rank sum test, and com-
parisons over intervals used repeated measures analysis of
variance for outcomes consistent with normal distributions and
the Wei–Johnson method of other outcomes. For changes
between times, the Wilcoxon signed rank test was applied to
differences. ELISpot response data were tested after a symme-
trizing power transformation (Box–Cox lambda=0.33) that
yielded normal residual distributions. Multiple pairwise tests
among the three immunized groups have been corrected by the
method of Hochberg.
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